The effects of various inhibitors on the regulation of orotic acid excretion in sparse-fur mutant mice (spf/Y) deficient in ornithine transcarbamylase.
Experiments were conducted to determine whether the excessive orotic aciduria, induced in sparse-fur male mice (spf/Y) deficient in ornithine transcarbamylase (OTC), may be regulated by some inhibitors, such as acivicin (0.014 mmol/100 g body weight, i.p.), N-(phosphonoacetyl)-L-aspartate (PALA, 2.5 mg/100 g body weight, i.p.), adenine (3 g/kg diet) and cycloheximide (0.35 mmol/kg body weight, i.p.). We also administered ornithine (1 mmol/100 g body weight, i.p.), a substrate of the urea cycle, to alleviate the metabolic deficiency of arginine in spf/Y mice which may also be responsible for excessive orotic aciduria. The orotic aciduria remained insensitive to acivicin, indicating mitochondria as the source of carbamyl phosphate. However, orotate excretion was significantly decreased by PALA (P < 0.01), due to its effect on the aspartate transcarbamylase activity. The ingestion of adenine resulted in an increase (P < 0.05) of urinary orotate, suggesting the blockage of the utilization of orotate for nucleotide biosynthesis. Ornithine administration led to a reduction (P < 0.01) of the excretion of orotate induced by the OTC deficiency in these mice, indicating that one of the regulatory steps in its synthesis may be the availability of ornithine. There were no changes in urinary orotate excretion in spf/Y mice when treated with cycloheximide. On the other hand, pretreatment with cycloheximide in an artificial model of OTC deficiency (Swiss-ICR normal mice on an arginine-deficient diet treated thereafter with norvaline, an inhibitor of OTC), caused a significant decrease in urinary orotate. These results suggest that spf/Y mice are unique in that the increased synthesis of orotate is not sensitive to cycloheximide. Perhaps this may reflect an adaptive phenomenon developed by the mutant mice to handle excess mitochondrial carbamyl phosphate and orotic acid.
Nelson
J
J
Department of Nutrition, University of Montreal, Quebec, Canada.
Qureshi
I A
IA
Vasudevan
S
S
Sarma
D S
DS
D000225:Adenine / Q000494:pharmacology*; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D003404:Creatinine / Q000652:urine; D003513:Cycloheximide / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007555:Isoxazoles / Q000494:pharmacology*; D008099:Liver / Q000201:enzymology; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D009952:Ornithine / Q000494:pharmacology; D020163:Ornithine Carbamoyltransferase Deficiency Disease; D009963:Orotic Acid / Q000037:antagonists & inhibitors / Q000652:urine*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology
D000963:Antimetabolites; D007555:Isoxazoles; D001224:Aspartic Acid; D009963:Orotic Acid; C013195:sparfosic acid; D003513:Cycloheximide; D003404:Creatinine; D009952:Ornithine; D000225:Adenine; D010746:Phosphonoacetic Acid; C006303:acivicin